Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPhospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic
Expert Opinion on Investigational Drugs, 09/18/09
Suckling KE – Phase II results of the trials of two phospholipase A2 inhibitors which may be of value in the treatment of atherosclerosis and cardiovascular disease have been reported in the past year. Darapladib (GlaxoSmithKline) is an inhibitor of lipoprotein–associated phospholipase A2 and varespladib (Anthera) inhibits several forms of the secreted phospholipase A2s. Despite the apparent similarity of mechanism, which is also built into the compounds' names, the role of the two types of phospholipase in atherogenesis is very different. Evidence for this comes from a range of preclinical studies and from epidemiological data which are summarised here. These data provide a basis for the Phase II studies and support decisions to move into Phase III, a decision which in the case of darapladib has been made and studies commenced (STABILITY trial). For varespladib the FRANCIS–ACS trial in acute coronary syndrome patients is in progress.
Related Articles
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia
Journal of Clinical Lipidology, 10/14/09
Relevance Score: 78%
Heritability of Thromboxane A2 and Prostaglandin E2 Biosynthetic Machinery in a Spanish Population
Arteriosclerosis, Thrombosis, and Vascular Biology, 10/26/09
Relevance Score: 64%
Increased levels of circulating microparticles in primary Sjogrens syndrome, systemic lupus erythematosus and rheumatoid arthritis, and relation with disease activity
Arthritis Research & Therapy, 10/20/09
Relevance Score: 64%
Impact of group IVA cytosolic phospholipase A2 gene polymorphisms on phenotypic features of patients with familial adenomatous polyposis
International Journal of Colorectal Disease, 10/08/09
Relevance Score: 64%
Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug
Atherosclerosis, 10/07/09
Relevance Score: 64%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Vernakalant hydrochloride for the treatment of atrial fibrillation
Expert Opinion on Investigational Drugs, 11/30/09
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
Vascular Health and Risk Management, 11/30/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/30/09
Sponsor
Article Search
Sponsor